Sectoral Asset Management
Latest statistics and disclosures from Sectoral Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are EVMN, CTNM, LLY, SI, UNH, and represent 30.93% of Sectoral Asset Management's stock portfolio.
- Added to shares of these 10 stocks: EVMN (+$10M), COGT, JNJ, AMGN, SI, SYK, ABT, LENZ, INSP, CARL.
- Started 6 new stock positions in INSP, NKTR, CARL, EVMN, LENZ, COGT.
- Reduced shares in these 10 stocks: GPCR (-$14M), VTYX (-$9.1M), RCUS (-$7.4M), ANAB (-$6.0M), IMTX (-$5.2M), BCAX, SLDB, KURA, MBX, .
- Sold out of its positions in ANAB, BCAX, BMY, CI, TIL, MBX, MLTX, PVLA, XBI, SLDB. PCVX, ZLAB, ZBIO, MRUS.
- Sectoral Asset Management was a net seller of stock by $-69M.
- Sectoral Asset Management has $125M in assets under management (AUM), dropping by -23.00%.
- Central Index Key (CIK): 0001274413
Tip: Access up to 7 years of quarterly data
Positions held by Sectoral Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Sectoral Asset Management
Sectoral Asset Management holds 74 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Evommune Com Shs (EVMN) | 8.1 | $10M | NEW | 589k | 17.12 |
|
| Contineum Therapeutics Cl A (CTNM) | 7.3 | $9.2M | 801k | 11.43 |
|
|
| Eli Lilly & Co. (LLY) | 6.3 | $7.8M | -22% | 7.3k | 1074.68 |
|
| Shoulder Innovations Common Stock (SI) | 5.6 | $7.0M | +14% | 492k | 14.30 |
|
| UnitedHealth (UNH) | 3.6 | $4.5M | 14k | 330.11 |
|
|
| Amgen (AMGN) | 3.4 | $4.3M | +26% | 13k | 327.31 |
|
| Johnson & Johnson (JNJ) | 3.4 | $4.2M | +32% | 20k | 206.95 |
|
| Abbvie (ABBV) | 3.1 | $3.8M | +13% | 17k | 228.49 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.9 | $3.6M | +3% | 8.0k | 453.36 |
|
| Abbott Laboratories (ABT) | 2.4 | $2.9M | +36% | 24k | 125.29 |
|
| Regeneron Pharmaceuticals (REGN) | 2.3 | $2.9M | -6% | 3.7k | 771.87 |
|
| Intuitive Surgic Com New (ISRG) | 2.2 | $2.7M | -15% | 4.9k | 566.36 |
|
| Boston Scientific Corporation (BSX) | 2.1 | $2.6M | +24% | 28k | 95.35 |
|
| Argenx Se Spn Sp Adr (ARGX) | 2.0 | $2.4M | -25% | 2.9k | 840.95 |
|
| Danaher Corporation (DHR) | 1.9 | $2.4M | 11k | 228.92 |
|
|
| Stryker Corporation (SYK) | 1.8 | $2.3M | +52% | 6.6k | 351.47 |
|
| Thermo Fisher Scientific (TMO) | 1.8 | $2.3M | 3.9k | 579.45 |
|
|
| Merck & Co (MRK) | 1.8 | $2.3M | +30% | 21k | 105.26 |
|
| Gilead Sciences (GILD) | 1.8 | $2.2M | -8% | 18k | 122.74 |
|
| Insmed Com Par $.01 (INSM) | 1.6 | $1.9M | -16% | 11k | 174.04 |
|
| Dex (DXCM) | 1.5 | $1.9M | +38% | 29k | 66.37 |
|
| Vera Therapeutics Cl A (VERA) | 1.5 | $1.9M | +22% | 37k | 50.64 |
|
| Structure Therapeutics Sp Adr (GPCR) | 1.3 | $1.7M | -89% | 24k | 69.55 |
|
| Biontech Se Sp Adr (BNTX) | 1.3 | $1.6M | -2% | 17k | 95.20 |
|
| Edwards Lifesciences (EW) | 1.2 | $1.5M | +15% | 17k | 85.25 |
|
| Astrazeneca Sp Adr | 1.1 | $1.4M | -18% | 15k | 91.93 |
|
| Summit Therapeutics (SMMT) | 1.1 | $1.4M | +7% | 80k | 17.49 |
|
| Arcus Biosciences Incorporated (RCUS) | 1.1 | $1.4M | -84% | 57k | 23.83 |
|
| Syndax Pharmaceuticals (SNDX) | 1.0 | $1.3M | -22% | 61k | 21.01 |
|
| Tarsus Pharmaceuticals (TARS) | 1.0 | $1.2M | -19% | 15k | 81.88 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.0 | $1.2M | -8% | 3.0k | 397.65 |
|
| Rapport Therapeutics (RAPP) | 0.9 | $1.2M | -10% | 39k | 30.34 |
|
| Cogent Biosciences (COGT) | 0.9 | $1.2M | NEW | 33k | 35.52 |
|
| Mineralys Therapeutics (MLYS) | 0.9 | $1.1M | -6% | 32k | 36.29 |
|
| Trevi Therapeutics (TRVI) | 0.8 | $1.1M | -20% | 84k | 12.52 |
|
| Roivant Sciences SHS (ROIV) | 0.8 | $984k | -9% | 45k | 21.70 |
|
| Tectonic Therapeutic (TECX) | 0.7 | $881k | -78% | 42k | 20.86 |
|
| Ventyx Biosciences (VTYX) | 0.7 | $875k | -91% | 97k | 9.03 |
|
| Bridgebio Pharma (BBIO) | 0.7 | $854k | -18% | 11k | 76.49 |
|
| United Therapeutics Corporation (UTHR) | 0.7 | $840k | +125% | 1.7k | 487.25 |
|
| Boundless Bio (BOLD) | 0.7 | $814k | 679k | 1.20 |
|
|
| Beone Medicines Sp Adr (ONC) | 0.6 | $810k | -62% | 2.7k | 303.81 |
|
| RadNet (RDNT) | 0.6 | $785k | +10% | 11k | 71.35 |
|
| Arrivent Biopharma (AVBP) | 0.6 | $770k | -2% | 38k | 20.12 |
|
| Uniqure SHS (QURE) | 0.6 | $732k | 31k | 23.93 |
|
|
| Ascendis Pharma Sp Adr (ASND) | 0.6 | $694k | -9% | 3.3k | 213.24 |
|
| Lenz Therapeutics (LENZ) | 0.5 | $680k | NEW | 43k | 16.00 |
|
| Pfizer (PFE) | 0.5 | $676k | -64% | 27k | 24.90 |
|
| Inspire Med Sys (INSP) | 0.5 | $664k | NEW | 7.2k | 92.23 |
|
| Ionis Pharmaceuticals (IONS) | 0.5 | $662k | -9% | 8.4k | 79.11 |
|
| Immatics Nv SHS (IMTX) | 0.5 | $662k | -88% | 63k | 10.50 |
|
| Hinge Health Cl A (HNGE) | 0.5 | $660k | +26% | 14k | 46.45 |
|
| BioMarin Pharmaceutical (BMRN) | 0.5 | $647k | -56% | 11k | 59.43 |
|
| Alignment Healthcare (ALHC) | 0.5 | $622k | -42% | 32k | 19.75 |
|
| Amicus Therapeutics (FOLD) | 0.5 | $617k | -63% | 43k | 14.24 |
|
| Privia Health Group (PRVA) | 0.5 | $617k | -28% | 26k | 23.71 |
|
| Carlsmed (CARL) | 0.5 | $589k | NEW | 48k | 12.35 |
|
| Ptc Therapeutics I (PTCT) | 0.5 | $586k | -9% | 7.7k | 75.96 |
|
| Omada Health (OMDA) | 0.5 | $576k | +32% | 37k | 15.78 |
|
| Nektar Therapeutics Com New (NKTR) | 0.5 | $570k | NEW | 14k | 42.28 |
|
| Kura Oncology (KURA) | 0.5 | $562k | -86% | 54k | 10.39 |
|
| Neurocrine Biosciences (NBIX) | 0.3 | $379k | -9% | 2.7k | 141.83 |
|
| Biogen Idec (BIIB) | 0.3 | $379k | -9% | 2.2k | 175.99 |
|
| Cytokinetics Com New (CYTK) | 0.3 | $374k | -42% | 5.9k | 63.54 |
|
| Jazz Pharma Shs Usd (JAZZ) | 0.3 | $348k | -8% | 2.0k | 170.00 |
|
| Silverback Therapeutics (SPRY) | 0.3 | $347k | -63% | 30k | 11.65 |
|
| Royalty Pharma Shs Class A (RPRX) | 0.3 | $327k | -8% | 8.5k | 38.64 |
|
| Illumina (ILMN) | 0.3 | $324k | -9% | 2.5k | 131.16 |
|
| Axsome Therapeutics (AXSM) | 0.3 | $318k | +70% | 1.7k | 182.64 |
|
| Incyte Corporation (INCY) | 0.2 | $272k | -9% | 2.8k | 98.77 |
|
| Tempus Ai Cl A (TEM) | 0.2 | $266k | +19% | 4.5k | 59.05 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.2 | $205k | -51% | 352.00 | 582.34 |
|
| Oric Pharmaceuticals (ORIC) | 0.1 | $184k | -93% | 23k | 8.18 |
|
| Moderna (MRNA) | 0.1 | $148k | -10% | 5.0k | 29.49 |
|
Past Filings by Sectoral Asset Management
SEC 13F filings are viewable for Sectoral Asset Management going back to 2010
- Sectoral Asset Management 2025 Q4 filed Feb. 9, 2026
- Sectoral Asset Management 2025 Q3 filed Nov. 14, 2025
- Sectoral Asset Management 2025 Q2 filed Aug. 14, 2025
- Sectoral Asset Management 2025 Q1 filed May 15, 2025
- Sectoral Asset Management 2024 Q4 filed Feb. 14, 2025
- Sectoral Asset Management 2024 Q3 filed Nov. 14, 2024
- Sectoral Asset Management 2024 Q2 filed Aug. 13, 2024
- Sectoral Asset Management 2024 Q1 filed May 14, 2024
- Sectoral Asset Management 2023 Q4 filed Feb. 14, 2024
- Sectoral Asset Management 2023 Q3 filed Nov. 14, 2023
- Sectoral Asset Management 2023 Q2 filed Aug. 11, 2023
- Sectoral Asset Management 2023 Q1 filed May 12, 2023
- Sectoral Asset Management 2022 Q4 filed Feb. 10, 2023
- Sectoral Asset Management 2022 Q3 filed Nov. 10, 2022
- Sectoral Asset Management 2022 Q2 filed Aug. 15, 2022
- Sectoral Asset Management 2022 Q1 filed May 10, 2022